Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.
St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.
GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.
A combination of Checkmate's TLR9 agonist and Merck's Keytruda reversed PD-1 resistance in melanoma patients.
Basilea extends its cancer pipeline by licensing ArQule’s phase 2-ready derazantinib, which slots in ahead of its in-house oncology programs.
The antibiotic cadazolid was one of two experimental assets J&J acquired in its $30 billion takeover of Actelion last year.
The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.
Will Johnson & Johnson be looking to beef up its pipeline with its R&D boost?
Apitope hopes to end a 60-year drought in new therapies for thyroid disorder Graves’ disease, which affects 10 million people in the U.S. and Europe.
After last year's phase 3 failure, Cyclacel is back with first-in-human results for a new drug that it hopes to pair with AbbVie's Venclexta.